$RCEL

Woody Joseph Fralin purchased $21K of RCEL

Woody Joseph Fralin purchased 5,200 shares of AVITA Medical, Inc. (RCEL) at $4.00 on 2026-06-09.

Original reporting
SEC EDGAR · Woody Joseph Fralin
Published Jun 11, 2026, 1:17 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$RCEL
Neutral
medium confidence
Mentioned
$RCEL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCELNeutralLow
01

Why it matters

A director’s open-market purchase is incremental information about insider sentiment, but it does not provide new clinical, regulatory, financial, or deal catalysts.

02

Market read

Traders may note the buy as a minor sentiment input, but it is unlikely to drive a sustained repricing without additional company-specific catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article provides no context on motivation, timing constraints, or whether other insiders/large holders acted similarly.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-10 for a 2026-06-09 insider buy

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for AVITA Medical, Inc.

Company-level read

Ticker impact

$RCELNeutralMedium confidence
Context

SEC Form 4 shows director Woody Joseph Fralin bought 5,200 shares of AVITA Medical (RCEL) for ~$20.8K on 2026-06-09.

Expected impact

Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The disclosure is a small, non-10b5-1 purchase by a director; without accompanying operational/news catalysts, it rarely changes fundamentals.

Market effects

No direct sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity/compensation-related and may not reflect a change in business outlook, especially at small dollar size.

Key entities

  • AVITA Medical, Inc.

    Subject of the Form 4 insider transaction; director Woody Joseph Fralin purchased shares.

  • Woody Joseph Fralin

    Director who reported an open-market purchase of 5,200 shares on 2026-06-09.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RCELMedAI 8/10

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

Avita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.

$RCELMedAI 8/10

AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript

AVITA Medical (RCEL) reported Q2 2026 revenue of $21.7M, up 18% year over year and 13% sequentially. RECELL revenue was $18.5M, Cohealyx $1.7M, and PermeaDerm $0.6M. Gross margin was 81.9%. Net loss was $7.7M ($0.25/share). Full-year 2026 guidance is $86M to $89M; cash flow breakeven targeted for Q4 2026.

$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.

$RCELHighAI 9/10

Why is Avita Medical stock surging 20% today?

Avita Medical (RCEL) shares rose about 22% pre-open after the company reported Q2 revenue of $21.7M, up 18% YoY and about 8% above consensus, with adjusted loss per share of $0.25 vs $0.30 expected. The firm raised 2026 revenue guidance to $86M-$89M and reiterated cash-flow breakeven in Q4 2026. BTIG upgraded RCEL to Buy and set a $7 target.

$RCELHigh

AVITA Medical, Inc. (RCEL): Results of Operations and Financial Condition

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care comp